Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, 375 Longwood Avenue, Boston, MA 02215, USA.
Emerging from a largely cytokine-based era, the last several years have witnessed a dramatic change in the therapeutic landscape of renal cancer. Molecularly targeted and antiangiogenic agents now form the backbone of most therapeutic strategies for patients with advanced renal cell carcinoma (RCC). Although the next few years may not see such broad paradigm shifts, there remains significant room for improvement in the care of patients with RCC. This review discusses challenges that face physicians and researchers as well as innovations that may contribute to improving the therapeutic outcomes for patients with RCC.
Written by:
Cho DC, Atkins MB. Are you the author?
Reference: Hematol Oncol Clin North Am. 2011 Aug;25(4):917-35.
doi: 10.1016/j.hoc.2011.05.001
PubMed Abstract
PMID: 21763974
UroToday.com Renal Cancer Section
